Skip to main content

Table 2 Incidence of acute intestinal GvHD > grade 2 until day 100 (p = 0.888 n.s.)

From: Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST)

 

Group

Total

Placebo

Budesonide

Acute intestinal GvHD grade 0-2

Number

37

42

79

%

86.0%

87.5%

86.8%

Acute intestinal GvHD grade 3-4

Number

6

6

12

%

14.0%

12.5%

13.2%

Total

43

48

91

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us